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Human skin has been shown to contain a high level of Sa-re-
ductase activity, the enzyme that catalyses the conversion of 
the weak androgen testosterone into dihydrotestosterone, 
the most potent androgen. Because two types of Sa-reductase 
genes have been characterized in humans, we have cloned 
Sa-reductase cDNAs from adult human keratinocyte and 
skin fibroblast cDNA libraries to identify and gain better 
knowledge of the Sa-reductase expressed in normal human 
skin. Nucleotide sequence analysis shows that the clones ob-
tained correspond to the type I Sa-reductase. RNase protec-
tion analysis using (poly A)+ RNA obtained from human skin 
and prostate also confirms that type I Sa-reductase is the 
predominant type expressed in normal skin, whereas type II 
T he skin possesses all the enzymes required for trans-formation of the inactive steroid precursors of adrenal origin, namely, dehydroepiandrosterone (DHEA) and its sulfate, DHEA-S, into active androgens and estrogens [1- 7]. Because the skin is the largest organ 
in the human body, this tissue can be considered as a major site of 
androgen formation . 
In addition to its function in normal skin physiology, Sa-reduc-
tase has been suggested as being involved in androgen-dependent 
disorders such as acne vulgaris, seborrhea, male pattern baldness, 
and idiopathic hirsutism [8 - 10]. Precise knowledge of the type(s) 
of Sa-reductase expressed in the skin thus becomes important for a 
better understanding not only of human skin physiology, but also of 
a more rational therapy for androgen-sensitive skin disorders. 
cDNA clones encoding two types of Sa-reductase have been iso-
lated from human prostate cDNA libraries [11,12] and have been 
chronologically identified as type I and type II Sa-reductases. The 
deduced amino acid sequences indicate that the two proteins possess 
60% homology and show different pH characteristics and sensibil-
ity to the inhibitor finasteride [12], the type II being strongly inhib-
ited by finasteride, whereas type I Sa-reductase is much less sensi-
tive to this compound. In addition, the structures of the types I and 
II Sa-reductase genes have been determined [13,14], the type II 
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Sa-reductase is the major form found in the prostate. Fol-
lowing polymerase chain reaction amplification of human 
keratinocyte and skin fibroblast cDNA, a low level of type II 
Sa-reductase cDNA has been detected. Using antipeptide 
antibodies raised in rabbits against the peptide sequence cov-
ering amino acids 227 - 240 to perform immunohistochemi-
cal localization of Sa-reductase, we have found that Sa-re-
ductase is distributed in sweat and sebaceous glands, as well as 
in the epidermal cell layers, thus providing the basis for the 
important role of androgens in human skin and its appen-
dages. Key words: 5a-reductase/steroidogenesis/skin/clolling/im-
munohistochemistry expression/endocrinology. ] Itwest Dermatol 
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being the major form expressed in the prostate and resronsible for 
male pseudohermaphroditism in deficient patients [15 . 
We have previously shown that human 3fi-hydroxysteroid dehy-
drogenase/.65-.64 isomerase (3fi-HSD) is also expressed in a tissue-
specific manner from two functiona l genes [16,17]. The type I 
3fi-HSD is almost exclusively expressed in the placenta [18] and 
skin [4], whereas type II 3fi-HSD is the major form expressed in the 
adrenals and gonads [19] and is responsible for congenital adrenal 
hyperplasia due to 3fi-HSD deficiency [20]. To gain a better knowl-
edge of the Sa-reductase expressed in human skin, we have isolated 
and elucidated the structure of cDNA clones isolated from adult 
human epidermal keratinocyte and human skin fibroblast cDNA 
libraries and we have determined the relative expression of type I 
and type II Sa-reductase in the prostate and skin, two main andro-
gen target tissues in the human. As human skin is composed of 
various cellular populations showing sensitivity to androgens, espe-
cially the epidermis, hair follicles, sebaceous glands, sweat glands, 
and dermis, polypeptide antibodies developed against fragments of 
type I Sa-reductase have been used to localize the enzyme by im-
munohistochemistry . 
MATERIALS AND METHODS 
Materials All restriction enzymes, T4 DNA ligase, and Klenow fragment 
of E. Coli DNA polymerase were obtained from Pharmacia (Canada) Inc, 
whereas Taq polymerase was from United States BiochemicaI Corp., 
(Cleveland, Ohio) and tritiated steroids were from Dupont (Canada) Inc. 
SW-13 adenocarcinoma cell s, a small cell carcinoma originating in the 
adrenal cortex of a Caucasian female, were obtained from the American 
Type Culture Collection (Rockville, MD); 4-MA (N,N-diethyl-4-methyl-
3-oxo-4-aza-5a-androstenc-17,B-carboxamide) and MK-906 (17,B-(N-t-
butyl) carbonoyl-4-aza-5a-androst-l-cne-3-one) were synthesized in the 
organic chemistry section of our laboratory. 
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Cloning and Sequence Determination Human epidermal keratino-
cyte and skin fibroblast cDNA libraries constructed in Agtll obtained from 
Clontech Laboratories Inc. (Palo Alto, CAl were screened with a human 
type I Sa-reductase eDNA probe labeled with (a-32P)dCTP by the random 
primer method [21]. Positive recombinant plaques were purified by replat-
ing twice and were grown in liquid culture medium. Phages were isolated by 
centrifugation for 90 min at 105,000 X g and DNA was isolated by phenol 
extraction. EcoRI restriction fragments obtained from phage DNA were 
subcloned into pCMV vector (kindly provided by Dr. Michael B. Mathews, 
Cold Spring Harbor Laboratories, NY) and plasmid DNA was prepared by 
alkaline lysis [22]. Sequencing of double-stranded plasmid DNA was per-
formed according to the dideoxy chain termination method [23] using mod-
ified T7 DNA polymerase [24] (Sequenase Kit, United States Biochemical 
Corp., Cleveland, OH). Oligonucleotide primers were synthesized in our 
laboratory with a Biosearch DNA synthesizer. 
Construction of Expression Vector and Transient Expression in Ad-
enocarcinoma (SW-13) Cells A cDNA fragment containing the entire 
coding region of type I 5a-reductase has been inserted downstream of the 
cytomegalovirus (CMV) promoter in the pCMV vector. Recombinant plas-
mids (pCMV -Sa-red) were prepared and purified using the Qiagen Mega kit 
(Qiagen Inc, Chatsworth, CAl. Fifteen micrograms of vector were used to 
transfect SW-13 cells by the calcium-phosphate procedure [25]. Cells were 
initially plated at 10' cells/cm2 in 7S-cm2 Falcon culture fl asks and grown in 
Dulbecco's modified Eagle's medium containing 10% (v/v) fetal bovine 
serum supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 100 
IU penicillin/ml, and 100 JLg streptomycin sulfate/ml. Cells were harvested 
by scraping with a rubber policeman and suspended in 0.5 ml buffer contain-
ing 50 mM potassium phosphate (pH 7.4), 20% glycerol, and 1 mM eth-
ylenediamine tetraacetic acid (EDTA) for enzymatic assay. 
Ribonuclease Protection Assay Regions containing 155 nucleotides 
spanning nucleotides 7 -161 downstream from the ATG start codon of 
human type I Sa-reductase and 319 nucleotides covering nucleotides 35-
353 of human type II Sa-reductase were obtained by amplification using the 
polymerase chain reaction (PCR). T he fragments obtained were subcloned 
in the Bluescript KS vector and sequenced in both directions. Type II recom-
binant plasmids were linearized with Not I and transcribed with [a_32P] 
UTP (800 Ci/mmol) (Amersham) to generate type-II-specific cRNA 
probes of 420 nuc1eotides using T3 RNA polymerase of the transprobe T kit 
(Pharmacia LKB Biotechnology), whereas type I recombinant plasmids 
were linearized with Hind III and a specific type I cRNA probe of 238 
nucleotides was generated by T7 RNA polymerase. Fifteen and ten micro-
grams of human poly(A)+ mRNA obtained from skin keratinocyte and 
prostate, respectively, were hybridized with 8 X 10' cpm of the type I or 
type II cRNA probe at 35°C for 14 h. Thereafter, RNA samples were diluted 
tenfold with 10 mM Tris-HCI (PH 7.5), 300 mM NaCI, and 5 mM EDTA 
in the presence of 40 JLg/ml RNase-A and 250 U/ml RNase-T1 and incu-
bated at 37"C for 1 h. Samples were then treated with a fina l concentration 
of 0.2 mg/ml proteinase-K and 0.5% sodium dodecyl sulfate for 15 min at 
37 °C, extracted, and purified as previously described [26]. RNase-resistant 
hybrids were analyzed by electrophoresis in a denaturating polyacrylamide 
urea sequencing gel. Signals were detected with a Phosphor Imager (Sunny-
vale, CAl. 
Analysis of Sa-Reductase Expression by PCR Using human prostate, 
skin fibroblast, and keratinocyte cDNA libraries (Clontech Laboratories 
Inc. , Palo Alto, CAl as sources of the mRNA(s) expressed in the prostate and 
skin, respectively, we amplified type I and type II Sa-reductases in the same 
tube with two pairs of the specific primers (5' -CCGCCTGTTGGTGGA-
AGAGAAGGAA-3', 5' -CGGAATTCGCACTT AAAACAAA-AA TGG-
AA T -3') and 5' -ATGCAGGTTCA-GTGCCAGCAGAG-3' , 5' -AAGT 
GGCC-AGGGCATAGCCTA-3'. The conditions used for Taq-PCR am-
plification were as described [1 6]. Pure preparations of type I and type II 
eDNA subclones were used as positive control templates, whereas a sample 
without DNA was used as negative control. The PCR products were sepa-
rated on 1 % agarose gel, transferred to rutrocellulose filters, and hybridized 
to oligonucleotide probes following the Southern procedure [27]. The oli-
goprobe was labeled wi th [32P] adenosine-S'-triphosphate (ATP) by T4 
nucleotide kinase and hybridized to the blots as described [28,29]. To avoid 
non-specific hybridization, the selected oligoprobe was chosen from regions 
different from the primers used for ampl ification. Autoradiography of the 
blots was quantified by densitometry using a Research Analysis System 
RAS-1000 (Loats and Assoc., Westminster, MA). 
Enzymatic Assay of Sa-Reductase Activity Transfected cells were 
incub~ted at 37 °C in 0.5 ml of 50 mM sodium phosphate buffer (PH 7.4) 
contam1l1g 20% glycerol, 1 mM EDTA, and 1 mM nicotinamide adenine 
dinucleotide (NADPH) + H+ for 1 h in the presence of the indicated con-
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centrations of radio labeled steroid substrate. Immediately after incubation, 
steroids were extracted and separated by thin-layer chromatography (TLC) 
as described [30). Radioactivity was measured by liquid scintillation spec-
trometry. The affinity constant was calculated by the program Enzfitter 
from Biosoft (Milltown, NJ). 
Antibody Preparation The peptide sequence NH2-CFLSGRAKEH_ 
HEWY -COOH located at amino acid position 227 - 240 was kindly synthe-
sized and purified on high-performance liquid chromatography (HPLC) by 
Dr. Serge St. Pierre, INRS Sante (Quebec). New Zealaud rabbits received a 
subcutaneous injection of 85 JLg peptide solubilized in 1 1111 phosphate-buf-
fered saline (PBS) containing 50% complete Freund's adjuvant. The animals 
received two booster injections with 40 JLg peptide in 50% incomplete 
Freund's adjuvant at 1-month intervals. Two weeks after the last injection, 
the animals were killed by decapitation and the blood was collected. The 
antiserum was obtained by decantation and separation by centrifugation 
before storage at - 80 ° C. 
Immunoblot Analysis Immunoblot was performed as previously de-
scribed [4]. Briefly, skin tissue from the pubic region was homogenized 
using a Polytron apparatus in a lysis buffer and electrophoresed on a 5-15% 
sodium dodecyl sulfate (50S) - polyacrylamide gel as described [31] before 
being transferred to rutrocellulose filters using a Bio-Rad apparatus for 4 h at 
70 V. Blots. were treated three. times withS% fat-fr.ee milk in PBS containing 
0.1 % NOlUdet P-40 for 30 mm. The antiserum raised against the peptide of 
type I Sa-reductase was added at a dilution of 1 : 1000 and incubated at 4 ° C 
for 18 h. The blot was then washed three times with PBS contairung 5% 
fat-f~e~ milk and 0.1 o~o Nonidet P-40. After washing, 12sl_labeled goat anti-
rabbit Immunoglobulin was added at a dilution of 1 /2000 before incubation 
for 4 h at 4°C. After three washes with the same buffer, blots were exposed 
to Kodak XAR-S films overmght at -80°C with an intensifying screen. 
Immunohistochemistry Human skin from the pubic region of adult 
women was fixed by immersion in4% paraformaldehyde for 2 h, dehydrated 
m a g.raded ethanol sen es, cleared III xylene, and embedded in paraffin. 
SIX-illicron sectIOns were then cut and mounted on glass slides. The sections 
were then deparaffinized in xylene for 10 min and dehydrated in 100% 
ethanol. Endogeneous peroxidase was blocked with methanol containing 
0.3% H 20 2 for 30 mill at room temperature, and washed in 0.05 M PBS 
buffer (pH 7.5). Non-specific im111unostaining was prevented by 3% normal 
goat serum (NGS) added for 45 min at room temperature. Samples were then 
i~cubated overrught at 4 ° C v.:ith rabbit serum anti-type I Sa-reductase at a 
dilution of 1 : 500 m 1% bOVlne serum albumin (BSA)-O.OS M phosphate 
buffer (pH 7.5). The shdes were then washed in the same buffer for 10 min 
and ~ncubated a.t room temperature for 30 min with biotinylated goat anti-
rabbit y-globulms (Zy~e? LaboratOries Inc., San Francisco, CAl diluted 
1 : 100 and washed ~galll m phosphate buffer for 10 min at room tempera-
ture. The streptaVldlll-peroxldase complex (Zymed) was added at a dilution 
of 1 : 100 111 BSA-O.OS M phosphate buffer and incubated fo r 30 min at room 
te~perature. The peroxidase activity was revealed following a 1S-min incu-
bation at room temperature in a medium containing 0.05% diaminobenzi_ 
dme and 0.03% H20 2. The sections were then counterstained with hema-
toxylin, cleared i~ xylene, and mounted with Permounr. In the negative 
controls: the rabbit antiserum was Immuno-absorbed overnight at 4 ° C with 
the peptide (1 mg/ml) used to ralse the antibodies. 
RESULTS 
Isolation and Characterization of Sa-Reductase cDNA from 
Human. Ski~ Human epidermal keratinocyte and skin fibroblast 
cDNA Itbranes constructed in Agtll were screened with a human 
type I cDNA probe ob~ained by amplification of a prostate cDNA 
library. Twelve and mneteen primary clones were isolated from 
about 500,000 }>laques from both libraries, respectively. Nucleotide 
sequence analYSIS showed that all these clones were identical to the 
sequen~e of hum a? type I Sa-reductase obtained from screening of a 
prostatic cDNA lIbrary [11] . As illustrated in Fig 1, transfection o f 
the expresslOn vector (pCMV-Sa-Red) in SW-13 cells indicates 
that the expressed enzyme efficiently catalyses the transformation 
of testosterone into dihydrotestosterone (DHT), whereas in non-
transfected cells, no enzymatic activity could be detected. 
To determine the substrate specificity of the Sa-reductase ex-
pressed in keratinocytes and skin fibroblasts, the homogenate o f 
SW-13 cells transfected with pCMV-5a-Red was used to deter-
mine the affinity constant (Km) of the expressed enzyme towards 
testosterone, 4-androstenedione, progesterone, cortisol, and corti-
costerone. As indicated in Table I , a similar Km, ranging from 
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Figure 1. Five-a-reductase activity of expressed eDNA encoding human 
keratinocyte Sa-reductase in SW-13 cells. Autoradiograph ofTLC of the 
transformation of 111M [14e] testosterone (T) to DHT by control mock-
transfected cells (control) and cells transfected with the pCMV -Sa-reduc-
tase expression vector (Transf). 
1.1 ± 0.2 to 5.1 ± 0.5 pM, was measured for all substrates tested 
except for cortisol, where the affinity constant was slightly higher at 
10 ± 1.1 nM. 
Relative Levels of Types I and II Sa-Reductase mRNAs in 
Skin Keratinocytes and Prostate The ribonuclease protection 
assay was used to determine the relative levels of expression of types 
I and II Sa-reductase mRNAs in the human prostate and skin kera-
tinocytes. As illustrated in Fig 2, when the type I antisense cRNA 
probe was used, the protected fragment of ISS base pairs (bp) was 
observed almost exclusively with keratinocyte mRNA, whereas 
only a barely detectable protected band could be detected with pros-
tate mRNA. On the contrary, when the type II antisense cRNA 
probe was used, the expected protected band was observed at 319 bp 
with prostatic mRNA, whereas, no signal could be detected with 
keratinocyte mRNA. 
To determine with higher sensitivity the presence of type I and/ 
or type II Sa-reductase(s), PCR amplification was performed as 
described under Materials and Methods. As can be seen in Fig 3, type II 
Sa-reductase was amplified at a very high level in the prostate, 
whereas a barely detectable level of type I Sa-reductase could be 
detected . In the keratinocyte and skin fibroblast cDNA libraries, the 
major form of Sa-reductase amplified by PCR was the type I Sa-re-
ductase, whereas the type II isoform was amplified at a much lower 
level. Quantification by densitometry of the signals obtained shows 
that the relative levels of the amplified types I and II Sa-reductase 
cDNAs are approximately 20 to 1 in keratinocytes and skin fibro-
blasts, whereas a ratio of 1 to 100 is obtained in the prostate. 
InllDunohistochemical Localization of Sa-Reductase Us-
ing antibodies raised against the synthetic peptide covering amino 
acids 227 - 240 of type I Sa-reductase, Western blot analysis indi-
Table I. Affinity Constant of Various Substrates for Human 








5.1 ± 0.5 
1.5 ± 0.2 
1.1 ± 0.23 
10 ± 1.1 
5.5 ± 0.6 
• The incubation and Km calculation were performed as described in M.teri.ls ."d 
Methods with substrate concentrations of 0.01, 0.025, 0.05, 0.10, 0.25, 0.5, 1,2.5,5, 10, 
25, and 50 ).1M. Data represent the mean ± so. 
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Figure 2. Ribonuclease protection analysis of the distribution of human 
type I and type II Sa-reductase mRNAs in human keratinocyte and prostate 
RNA. Sa~pl es of poly(A) + RNA ob:ained from human prostate (15 J.lg) 
and keratmocytes (10 J.lg) were hybndized as described in Materials and 
Methods with probes for types I and II Sa-reductase. The longest protected 
fragments (155 and 319 nucleotides, respectively) correspond to the homol-
ogous RNA species protected by the cRNA probe. 
cates that the antibody cross-reacts specifically with one ~rotein 
band tha.t corresponds to the molecular size of Sa-reductase (Fig 4). 
The antiserum was then used to perform immunohistochemical 
loc~lization of S.a-reductase in human skin. As can be seen in Fi'g. S, 
a high l~vel of IUlluunoreactivity was found in the epidermal cell 
layers (Fig Sa), se.baceous glands (Fig Sb), and sweat glands (Fig Sc), 
whereas no reaction could be detected in an immunoabsorbed con-
trol (Fig Sd). 
DISCUSSION 
T.he prese~t study d.esc~ibes the cloning, expression, and immuno-
htstochemlcal localtzatton of Sa-reductase in the skin. The ap-
proaches used penUlt us to show that the almost exclusive Sa-re-
ductase gene express.ed in human skin is the type I isoform. 
Moreover, uumunohlstochemical localization shows that Sa-re-
ductase is located in the various layers of the epidermis, in the 
sebaceous ~lands~ as well as in the sweat glands. Recently, we have 
shown, uSll1g a Similar approach, that skin 3ft-HSD is localized in 
the sebaceous glands [4] . 
On the othe~ hand, the type II Sa-reductase is the predominant 
type expressed ~n the h~man prostate a.nd is responsible for Sa-re-
ductase congel11tal defiCiency [12J. In these patients deficient in type 
II Sa-reductase, low but detectable levels of circulating DHT have 
?een observed. Because the type I Sa-reductase is not altered [12J, it 
IS reasonable to suggest that the circulating DHT in these deficient 
patients originates from the skin and/or other tissues expressing 
mtact type I Sa-reductase. As mentioned earlier, because the skin is 
the largest organ in the human body, this tissue should be consid-
ered an important site of androgen formation. 
Sebum secretion, body hair growth, and androgen-dependent 
hair loss or androgenic alopecia have been shown to be under the 
control of the potent androgen DHT, the product of the conversion 
of testosterone into DHT by the enzyme Sa-reductase [8-10J. As 
mentioned earlier, the skin possesses all the steroidogenic enzymes 
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Type 1-
Type II -
Figure 3. Quantification by PCR amplification of types I and II Sa-reduc-
tase present in human prostate as well as keratinocyte and skin fibroblast 
cDNA libraries. Control contained 20 ng of the type I and type II Sa-reduc-
tase cDNA clones inserted in the pCMV vector, whereas SOO ng of DNA 
obtained from the prostate, keratinocyte, and skin fibroblast cDNA libraries 
constructed into Agt11 were used for amplification. Amplification and quan-
tification were performed as described in Materials and Methods . 
required to convert the inactive androgen precursors DHEA and 
DHEA-S into active androgens [1-7]. In fact, the human skin has 
been shown to convert DHEA into androstenedione [32], which is 
then transformed into testosterone [5,6,33]. The importance of 
these enzymes is well supported by the observation that DHEA can 
stimulate sebaceous gland secretion in humans [2,34]. 
At puberty, the increase in the secretion of DHEA, especially the 
secretion of its sulfated form, DHEA-S [35]' is associated with an 
increase in sebaceous gland size and sebum production [36,37], 
which frequently lead to problems of acne [38,39]. In fact, an eleva-
tion in skin Sa-reductase [8,10,40] and 3P-HSD [41] activities has 
been described in hirsutism and acne. Because sebaceous gland size 
has been found to be increased in hirsutism and acne [42,43] and 
Sa-reductase (present data) as well as 3P-HSD [4] are localized in 
sebaceous glands in humans, the increase in Sa-reductase and an-
drogen formation in the skin of such patients [8,10] could be a cause 
or an effect of increased sebaceous gland volume. It should also be 
mentioned that the metabolism of DHEA has been found to be 
higher in the skin from hirsute compared to normal women [10]. 
The presence of 3P-HSD, 17P-HSD, and Sa-reductase in the 
sebaceous glands may allow the sebaceous glands to develop fully in 
both boys and girls in utero and at puberty at the time of increased 
DHEA and DHEA-S formation by the ad rena Is [44]. Five a-reduc-
tase is thus likely to playa major role during intrauterine life when 
the sebaceous glands develop to a state of maturity in both male and 
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Figure 4. Immunoblot analysis 
of human pubic skin. Experi-
mental procedure was as de-
scribed in Materials alld Methods. 
Sixty and 120 f.l.g of protein were 
used in lalles A and B, respec-
tively. 
version ofDHEA and DHEA-S by 3P-HSD, 17P-HSD, and Sa-re-
ductase. 
The lower Km of cortisol for the expressed type I Sa-reductase 
agrees with the results of Voigt et al [4SJ, who showed that cortisol 
and cortisone are less potent inhibitors of the transformation of 
testosterone to DHT by human skin than prostate Sa-reductase. 
Because Sa-reductase is unstable, the enzyme could not yet be puri-
fied to homogeneity, and antibodies against the purified protein are 
not available. Our study is the first to report immunocytochemical 
localization of Sa-reductase using antipeptide antibodies. The 
present data clearly indicate that skin Sa-reductase is localized in the 
androgen-sensitive skin and its appendages, namely the sebaceous 
glands, sweat glands, and epidermis. Such data are in agreement 
with the localization of enzymatic activity in skin biopsies [7] and in 
tissue microdissected from freeze-dried skin [46] . Whether Sa-re-
ductase has a cytoplasmic or nuclear localization, or both, has not 
been clearly defined [47 -49]. Our immunocytochemical determi-
nation strongly indicates that the type I Sa-reductase in the skin is 
distributed in both the cytoplasm and the nucleus. In our previous 
studies [4], we have described the immunologic localization of 3P-
HSD in the sebaceous glands. The presence in the sebaceous glands 
of3P-HSD, 17p-HSD [50], and Sa-reductase, or of all the enzymes 
required to transform DHEA into DHT, the ultimate androgen, 
strongly suggests that the sebaceous glands are able to transform 
DHEA present at high levels in the circulation [3,51] into DHT. In 
the skin, DHEA is likely formed from DHEA-S [51]' the most 
abundant circulating steroid in man, by the action of steroid sulfa-
tase, a widely distributed enzyme [52]. 
Because receptors for androgens, estrogens, and glucocorticoids 
have been found in human skin [53], it is likely that the steroids 
synthesized in the skin from the inactive adrenal precursors exert 
major intracrine effects in the same cells where they are produced 
[3]. These steroids could also exert a major paracrine effect on 
neighboring cells and it is likely that some steroids released from the 
skin cells reach the general circulation and exert endocrine effects in 
distant target tissues. The isolation of cDNAs encoding Sa-reduc-
tase and its subtissular localization in the human skin provide useful 
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Figure S. Immunohistochemical localization of Sa-reductase in human 
skin. Immunostaining for Sa-reductase can be seen in the cytoplasm and the 
nucleus of the epidermal cell layers (a), sebaceous gland (arrow, b) and sweat 
glands (arrows). An immunoabsorb~d .control is shown i~l (d) .. Conditi.ons for 
preparing samples and Immunostammg were as descnbed m Matenals and 
Methods. Bar, 10 J1m (a, d) and 20 J1m (b, c), respectively. 
tools for detailed studies of the endocrine regulation of androgen 
biosynthesis and action in the skin. 
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